Autologous Bone Marrow Mesenchymal Stem Cell Therapy Offers New Hope for Patients with Infertility Caused by Recurrent Intrauterine Adhesions

In collaboration with Shengjing Hospital of China Medical University, Shenyang Cell Center has participated in clinical research investigating a new cell-based treatment approach using autologous bone marrow mesenchymal stem cells (BM-MSCs) for women with infertility caused by recurrent intrauterine adhesions (IUA). This research was published in the internationally renowned journal Archives of Gynecology and Obstetrics.

 

 

 

IUA is a challenging condition that can result in amenorrhea, infertility, and recurrent miscarriage. Despite conventional surgical treatment, some patients continue to suffer from repeated adhesion formation and difficulty achieving pregnancy.

 

 

We selected seven patients with recurrent intrauterine adhesions between 2017 and 2020 who had failed to respond to conventional treatment such as hysteroscopic adhesiolysis. Patients received three intrauterine perfusions of their own BM-MSCs after surgery. By promoting revascularization and angiogenesis—two processes essential for normal tissue healing—these stem cells help improve endometrial thickness and support the restoration of a healthier uterine environment.

The results were encouraging. Follow-up showed improvements in endometrial thickness and blood flow, and no new intrauterine adhesions were observed during the study period. Importantly, two patients went on to achieve successful full-term deliveries.

 

 

Shenyang Cell Center provided the stem cell manufacturing technology that supported clinicians in exploring cell-based therapies. All autologous BM-MSCs prepared by Shenyang Cell Center met the standards required for clinical application. No adverse events or treatment-related symptoms were observed in any of the seven patients after cell therapy.